DEVELOPING ORAL BIOLOGICS THAT ACT ON CELLS IN THE SMALL INTESTINE WITH SYSTEMIC THERAPEUTIC EFFECTS

Cells in the small intestine play a central role in governing our immune, metabolic and neurological systems.

Our first product candidates are single strains of microbes selected for defined pharmacological properties.

Our therapies have the potential to be effective, safe and affordable medicines to improve the lives of people with chronic diseases and cancer.

About our science

Our Platform

  • We have developed an integrated platform to develop oral biologics which harness the central role that cells in the small intestine play in governing our immune, metabolic and neurological systems.
  • The efficiency of our platform has allowed us to produce, in a relatively short period of time, product candidates for a range of inflammatory diseases and cancer.

Our Portfolio

We currently have four product candidates: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases, and EDP1503 for the treatment of cancer. We are also advancing additional oral biologics through preclinical development in other disease areas.

About our portfolio

Evelo is led by a team with deep experience.

Our leadership team has founded, led, and grown transformative platform biotechnology companies. Our team has also developed and commercialized medicines that have impacted many lives.

About our team

Investors

For investor and shareholder resources, please visit the link below.

Investors page

The destination for pioneers and adventurers

If you want to join an exceptional team and culture that is committed to driving profound benefits to patients and society, let us know.

Careers page

Contact

620 Memorial Drive, 5th Floor
Cambridge, MA, 02139 USA

Hobday Building, The London BioScience Innovation Centre
2 Royal College Street, London, NW1 0NH, UK

For general inquiries contact:
info@evelobio.com

For media inquiries contact:
media@evelobio.com

For investor inquiries contact:
ir@evelobio.com